A Digital Publication for the Practicing Medical Specialist, Industry Executive & Investor

No Carolina / New York

Ceros Financial Services Arranges $15 Million Financing For GT Metabolic Solutions

Ceros Financial Services announced that Ceros Capital Markets, its investment banking division, has completed an approximately $15 million Series A round for GT Metabolic Solutions, which has developed minimally-invasive incisionless bypass technology for bariatric, metabolic and digestive surgery.

Ceros Financial Services will apply the raise to complete initial clinical trials for its incisionless Duodenal Ilial Bypass anastomosis for bariatric and metabolic surgery.

GT Metabolic’s technology enables incisionless bariatric surgery and involves no cutting, no suturing and no permanent implant, enabling these procedures to move to the outpatient surgical setting. The platform works by creating a delayed anastamosis, a technique that involves the use of magnets to connect the tissue and create an anastomosis in a delayed manner without incision and the risk of creating a leak.  The company was co-founded by Thierry Thaure, who has 40 years of experience as a medtech entrepreneur, and pioneer surgeon Michel Gagner, M.D., laparoscopic and bariatric surgeon who invented the LapSleeve procedure for bariatric surgery, and who also serves as GT’s Chief Medical Officer.

“We believe that GT Metabolic has created game-changing technology for bariatric surgery to help patients struggling with obesity, a growing and expensive epidemic that leads to other serious health conditions. Too few options currently exist for the surgeon today.  The company’s platform is designed to be safer for the surgeon and patient, and more cost-efficient for the healthcare system,” said Mark Goldwasser, CEO of Ceros Financial Services.

“We have developed our platform with the goal of revolutionizing bariatric and metabolic surgery. GT’s technology enables a new portfolio of procedures that will complement and expand the market.  We look forward to moving ahead with our clinical trials and in time commercialization of our technology globally,” Thaure said.

According to data from the CDC, the US obesity prevalence was 41.9% in 2017 to March 2020.  The estimated annual medical cost of obesity in the United States was nearly $173 million in 2019 dollars.

Ceros focuses on fundraising for early-stage medical technology and medical device companies that are developing disruptive technologies, particularly for diagnostic and non-invasive procedures.  Ceros completed $117 million in transactions in the medtech sector in 2021 and $145 million since 2020.  The firm is targeting to raise $150 million this year, Goldwasser said.

In June, Ceros and Peregrine Ventures led an $18 million financing round for Cordio Medical, which has developed technology to monitor chronic heart failure conditions by analyzing voice recordings in a simple smartphone app.

Ceros also recently placed an additional $10 million for DemaSensor, which designs non-invasive tools that use machine learning and spectroscopy to evaluate skin lesions for cancer.  Ceros was an existing investor in the company.  Earlier this year, the firm announced a $15 million placement for Pristine Surgical, which has developed a single-use platform for endoscopic procedures.

 

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

With this new investment partnership, E Tech Group expects to accelerate organic growth and acquisition to become a top system integrator in North America.
The investment will allow ROM InWest to further distribute its fall detection product globally.
Nawal Ouzren, Sensorion’s Chief Executive Officer, said: “We are thrilled to announce another successful capital raise, securing an additional EUR 15 million to accommodate interest expressed by certain existing investors. This builds on the earlier EUR 50 million financing announced in February 2024, adding up to a total of EUR 100 million raised in less than 9 months. With this new financing, we are well-positioned to accelerate our gene therapy programs, including the progression of SENS-501 through its Phase 1/2 clinical study, Audiogene, and the advancement of our second program, GJB2-GT, towards Clinical Trial Applications submission in H1 2025. The capital increase enables the Company to finance its activities until the end of 2025. We remain deeply thankful for the ongoing support of our shareholders and partners as we strive to make a meaningful difference in the lives of those affected by hearing loss disorders.”
Strategic Investor, Osang Healthcare will partner with Kryptos Biotechnologies for the manufacturing and distribution of the product along with financing.
Proceeds from the financing will advance Obsidian’s lead engineered tumor-infiltrating lymphocyte (TIL) program, OBX-115, in its ongoing trials for patients with melanoma and non-small cell lung cancer (NSCLC). Obsidian Therapeutics is focused on enrolling patients and reaching key clinical and regulatory milestones, as well as manufacturing scale-up ahead of pivotal trial readiness.

By using this website you agree to accept Medical Device News Magazine Privacy Policy